In terms of 'increasing investment in research and development', substantial resources have been allocated from the Research Framework Programmes for HIV/AIDS, malaria and TB research, including the establishment of the new European and Developing Countries Clinical Trials Partnership (EDCTP) initiative which is the first joint programme to bring together the efforts of several Member States aimed at developing and evaluating new vaccines and drugs against those diseases.

Support will be given to Preclinical and early clinical testing of new drugs, vaccines and microbicides for HIV/AIDS, malaria and TB.

Research will focus on: developing promising candidate interventions (vaccines, therapies and HIV microbicides) against the target diseases by sponsoring research over the full spectrum from basic molecular research, taking advantage of microbial genomics, through to pre-clinical testing and proof-of-principle; establishing a clinical trials programme to unite and support Europe's clinical trial activities specifically targeted at interventions for use in developing countries; establishing an AIDS Therapy Trials Network in Europe to improve the coherence and complementarity of clinical trials of AIDS therapies for European use.

Research will focus on: developing promising candidate interventions (vaccines, therapies and HIV microbicides) against the target diseases by sponsoring research over the full spectrum from basic molecular research, taking advantage of microbial genomics, through to pre-clinical testing and proof-of-principle; establishing a clinical trials programme to unite and support Europe"s clinical trial activities specifically targeted at interventions for use in developing countries; establishing an AIDS Therapy Trials Network in Europe to improve the coherence and complementarity of clinical trials of AIDS therapies for European use.

Research will focus on: developing promising candidate interventions (vaccines, therapies and HIV microbicides and evaluation criteria on the various interventions and the effects on public health ) against the target diseases by sponsoring research over the full spectrum from basic molecular research, taking advantage of microbial genomics, through to pre-clinical testing and proof-of-principle; establishing a clinical trials programme to unite and support Europe"s clinical trial activities specifically targeted at interventions for use in developing countries; establishing an AIDS Prevention (vaccines) and Therapy Trials Network in E ...[+++]urope to improve the coherence and complementarity of clinical trials of AIDS therapies for European use.

In addition, the EU is contributing to the development of new drugs and vaccines against communicable diseases, inter alia through the European and Developing countries Clinical Trials Partnerships (EDCTP). In response to the Council’s request,[xxvii] the Commission should, together with the Member States, develop a roadmap on possible joint action based on the European Programme for Action to confront HIV/AIDS, malaria and tuberculosis.[xxviii] The EU should, in this context, promote synergies and provide a coherent and coordinated response to the three diseases across relevant policy areas.[xxix] In this sense, the Commission intends t ...[+++]o put forward a Communication on combating HIV/AIDS within the European Union and the Neighbouring countries later this year.